Herantis Pharma (HEL: HRTIS)

Last close As at 07/10/2025

EUR2.72

0.21 (8.37%)

Market capitalisation

EUR61m

Herantis Pharma is a Finland-based clinical-stage biotechnology company focused on developing disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases.

Latest Insights

View More

Healthcare | Spotlight — flash

Herantis Pharma — HER-096 clears Phase Ib, eyes Phase II

Healthcare | Spotlight — update

Herantis Pharma — H125 results reflect Phase Ib progress

Healthcare | Spotlight — flash

Herantis Pharma — Last patient visit completed for Phase Ib

Healthcare | Spotlight — initiation

Herantis Pharma — Dedicated to disease modification for PD

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Antti Vuolanto

    CEO

  • Tone Kvåle

    CFO

Research

Spotlight — initiation

Healthcare

Herantis Pharma — Dedicated to disease modification for PD

edison tv

Healthcare

Herantis Pharma – executive interview

Non client QV

Healthcare

Herantis Pharma — Potential disease-modifier for PD

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free